• Small Molecules
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

SynVent IDD platform

SynVent: Experienced at every step – concept to clinic

SynVent’s current portfolio across  integrated drug discovery projects and therapeutic areas.

We collaborate with a diverse range of organizations, each of which faces distinct challenges:

  • Virtual biotech companies that bring innovative approaches to a target or pathway and need support to transform their concepts into tangible outcomes
  • Small biotech companies equipped with groundbreaking platform technologies but need support for the remaining stages of their drug discovery process
  • Mid-sized and large pharmaceutical companies looking to outsource a drug discovery program while minimizing overhead costs to deliver a candidate
  • University spin-outs seeking a collaborator to validate and develop their ideas to facilitate their next round of funding
  • Non-profit organizations in search of a partner with extensive expertise across target classes and therapeutic domains to address unmet diseases
  • Venture capital funders who need a dependable, expert team to effectively guide a program toward a go/no-go decision.

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details